Pertussis Vaccine Market Size & Share, By Product Type (Dtap Vaccine and Tdap Vaccine), End-User (Vaccination Centers, Hospitals, Clinics), Regional Forecast, Industry Players, Growth Statistics Report 2024-2035

Market Outlook:

Pertussis Vaccine Market size exceeded USD 8.18 Billion in 2023 and is estimated to cross USD 19.64 Billion by 2035, growing at over 10.84% CAGR during 2024 to 2035.

• Base Year Value (2023): USD 8.18 Billion
• CAGR (2024-2035): 10.84%
• Forecast Year Value (2035): USD 19.64 Billion
• Historical Data Period: 2019-2022
• Largest Region: North America
• Forecast Period: 2024-2035

Market Dynamics:

Pertussis, also known as whooping cough, is a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. The pertussis vaccine market is driven by the increasing awareness of the disease and the need for vaccination to prevent its spread. The global pertussis vaccine market is expected to grow at a steady pace due to the rising incidence of pertussis and the growing emphasis on immunization programs.

Growth Drivers & Opportunities:

One of the key growth drivers for the pertussis vaccine market is the increasing government initiatives and funding for immunization programs. Many countries around the world have stringent vaccination schedules for infants and young children, which has led to a steady demand for pertussis vaccines. Additionally, the growing awareness about the importance of vaccination among parents and healthcare professionals is also contributing to the growth of the market.

Furthermore, the development of combination vaccines that include pertussis antigens along with other vaccines, such as diphtheria and tetanus, has also propelled the growth of the pertussis vaccine market. Combination vaccines offer the benefit of reducing the number of injections required for immunization, thus increasing patient compliance and convenience.

Report Scope

Report Coverage	Details
Segments Covered	By Product Type, End-User
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	Protein Sciences, GlaxoSmithKline, Sanofi Pasteur, Seqirus, Merck Sharp & Dohme Corp., Novartis AG, and Astellas Pharma US,

Industry Restraints & Challenges:

Despite the growth drivers, the pertussis vaccine market also faces several restraints and challenges. One of the major challenges is the high cost associated with vaccine production and distribution. This has led to a widening gap in access to pertussis vaccines, particularly in low- and middle-income countries. Furthermore, the lack of awareness about the disease and the importance of vaccination in some regions has hindered market growth.

Another challenge for the pertussis vaccine market is the occurrence of adverse events following immunization (AEFIs). Although rare, AEFIs can lead to vaccine hesitancy among some individuals and communities, impacting the uptake of pertussis vaccines.

Regional Forecast:

North America:

North America is expected to dominate the pertussis vaccine market due to the high incidence of pertussis in the region. The United States, in particular, has witnessed several pertussis outbreaks in recent years, leading to an increased focus on vaccination. The presence of major vaccine manufacturers and ongoing research and development activities further contribute to the growth of the market in North America.

Asia Pacific:

The Asia Pacific region is expected to experience significant growth in the pertussis vaccine market due to the expanding immunization programs and the rising awareness of the disease. Countries such as China and India have large birth cohorts, which present a substantial market opportunity for pertussis vaccines. Additionally, the increase in disposable income and the growing healthcare infrastructure in the region will further drive market growth.

Europe:

Europe is also expected to contribute to the growth of the pertussis vaccine market due to the strong support for immunization programs and the high prevalence of pertussis in some European countries. The presence of key market players and the emphasis on research and development activities will bolster market growth in the region.

In conclusion, the pertussis vaccine market is expected to grow steadily due to the increasing awareness of the disease and the importance of vaccination. Government initiatives, the development of combination vaccines, and the expansion of immunization programs will continue to drive market growth. However, challenges such as cost constraints and vaccine hesitancy need to be addressed to fully tap into the market potential. The regional forecast indicates significant growth opportunities in North America, Asia Pacific, and Europe, providing a positive outlook for the pertussis vaccine market.

Segmentation Analysis:

Whole-Cell Pertussis Vaccine

Whole-cell pertussis vaccine, also known as the DTP vaccine, has been historically used to protect against pertussis. This vaccine contains a whole, but inactivated, pertussis bacteria along with tetanus and diphtheria toxoids. The whole-cell vaccine has been associated with a higher risk of side effects such as fever, fussiness, and soreness at the injection site compared to the newer acellular pertussis vaccines. Despite this, it continues to be used in some countries and may still play a significant role in the pertussis vaccine market.

Acellular Pertussis Vaccine

Acellular pertussis vaccines, also known as the DTaP or Tdap vaccines, contain only specific components of the pertussis bacteria that are believed to provide immunity. These vaccines have been developed to reduce the risk of side effects associated with the whole-cell vaccines while still providing protection against pertussis. The acellular pertussis vaccines are now commonly used in many countries as part of routine childhood immunization schedules. They are also recommended for adolescents and adults as boosters to maintain immunity.

Competitive Landscape:

The pertussis vaccine market is highly competitive with a few key players dominating the industry. These companies are continuously investing in research and development to enhance their product portfolios and gain a competitive edge. Some of the major players in the pertussis vaccine market include GlaxoSmithKline, Sanofi Pasteur, Merck & Co., and Pfizer. These companies have a strong presence in both developed and developing markets, and they are constantly engaged in strategic partnerships and collaborations to expand their global footprint.

In addition to these multinational pharmaceutical companies, there are also several smaller players that are actively involved in the development and distribution of pertussis vaccines. These companies play a crucial role in driving innovation and providing alternative options in the market.

The competitive landscape of the pertussis vaccine market is characterized by intense competition, and companies are focusing on new product launches, strategic alliances, and mergers and acquisitions to strengthen their position. The market is also witnessing an increasing focus on the development of combination vaccines that offer protection against multiple diseases, including pertussis. This trend is expected to further intensify the competition and shape the market dynamics in the coming years.